Equities

SeQuent Scientific Ltd

SEQUENT:NSI

SeQuent Scientific Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)173.44
  • Today's Change1.64 / 0.95%
  • Shares traded1.22m
  • 1 Year change+93.90%
  • Beta0.5541
Data delayed at least 15 minutes, as of Sep 20 2024 11:25 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SeQuent Scientific Limited is an India-based animal health company. The Company provides a wide range of animal health products, including finished dose formulations, active pharmaceutical ingredients (APIs), as well as analytical services. The Company operates through the pharmaceuticals segment. The Company is focused on various therapies, such as targeted are anthelmintics (endo and ecto parasiticides), anti-protozoals, nutraceuticals, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-infectives and dermatology. It is specialized in analytical and bio analytical services to support the API, pharmaceutical, personal care and nutraceutical companies. It provides analytical solutions, including method validation, stability, microbiology for APIs and finished products in a variety of dosage forms as per pharmacopoeia monographs, customer developed methods or in-house method development. The Company’s subsidiaries include Alivira Animal Health Limited and SeQuent Research Limited.

  • Revenue in INR (TTM)14.27bn
  • Net income in INR54.87m
  • Incorporated1985
  • Employees1.20k
  • Location
    SeQuent Scientific Ltd301/A, 3rd Floor,Dosti Pinnacle,, Plot No.E7,Road No. 22MUMBAI 400604IndiaIND
  • Phone+91 2 241114777
  • Fax+91 2 241114754
  • Websitehttps://sequent.in/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
IOL Chemicals and Pharmaceuticals Ltd.20.72bn1.19bn28.29bn2.78k23.86--15.301.3720.2020.20353.05--------7,461,253.00--14.91--19.4533.9634.545.7212.00--10.06--10.59-3.804.82-3.39-10.7035.27--
Dishman Carbogen Amcis Ltd24.16bn-2.48bn28.62bn1.13k----165.731.18-15.81-15.81154.06--------21,344,260.00---0.3986---0.488879.3073.83-10.27-1.54---0.7216----8.414.91-414.93---0.3175--
SMS Pharmaceuticals Ltd7.38bn569.64m30.22bn1.20k52.89--33.964.096.756.7587.48--------6,168,549.00--5.43--7.3330.1233.307.697.87--4.21--6.1735.868.81805.824.478.419.86
Solara Active Pharma Sciences Ltd13.00bn-5.61bn31.68bn2.16k------2.44-143.75-143.75334.17--------6,030,149.00---2.44---3.8437.3441.16-43.17-4.49---1.57-----10.73-1.45-2,458.12---4.81--
Indoco Remedies Ltd18.22bn766.90m34.06bn5.93k44.80--19.561.878.258.25178.33--------3,072,462.00--6.88--9.8568.6165.594.106.93--2.95--14.028.9113.41-30.78--34.5437.97
Jeena Sikho Lifecare Ltd-100.00bn-100.00bn34.42bn1.23k--108.86----------12.72------------------------0.8228--0.2681--43.84--77.37------
RPG Life Sciences Limited6.00bn923.20m34.94bn1.27k37.84--31.635.8355.8255.82362.60--------4,721,969.00--16.07--21.7768.4262.9915.3911.99--220.43--29.2713.5012.0129.6051.9828.6046.14
Gufic BioSciences Ltd8.14bn863.69m40.16bn1.45k46.04--38.824.938.708.7081.95--------5,624,707.00--11.46--19.2152.3945.7910.6010.46--8.09--1.3116.8018.128.0731.4653.8314.87
SeQuent Scientific Ltd14.27bn54.87m43.00bn1.20k807.64--55.353.010.21370.213757.18--------11,939,190.00--1.09--1.7645.3841.970.99021.18--0.9009--35.06-3.605.6870.40--6.96--
Innova Captab Ltd11.42bn1.06bn44.28bn--32.66--35.643.8823.6923.69236.62------------10.82--18.3833.3825.189.308.04--8.89----16.7224.9038.8436.55104.14--
Unichem Laboratories Ltd17.28bn-605.50m45.11bn3.19k----86.352.61-8.59-8.59245.15--------5,410,587.00---1.67---2.0362.0056.18-3.50-3.99--0.1401----26.947.6465.15---35.00--
Morepen Laboratories Ltd17.45bn1.18bn45.91bn1.62k36.26--30.682.632.312.3134.26--------10,749,300.00--7.90--13.3437.8633.346.775.49--33.34--0.0019.2517.08148.6327.2247.03--
Hikal Ltd18.03bn677.82m46.42bn2.06k68.52--24.502.575.495.49145.97--------8,749,879.00--5.07--7.5153.0646.783.765.86--2.45--12.19-11.792.34-11.20-7.559.720.00
Aarti Drugs Ltd24.23bn1.57bn47.68bn1.06k30.36--22.801.9717.0817.08263.82--------22,770,740.00--9.73--15.7834.3222.236.488.25--7.28-----6.9010.133.0713.8224.96--
Supriya Lifescience Ltd5.99bn1.35bn49.03bn448.0036.26--32.318.1916.8016.8074.42--------13,370,000.00--19.08--24.0462.7557.1222.5824.71--92.47--2.8823.7415.4732.5624.7583.79--
Data as of Sep 20 2024. Currency figures normalised to SeQuent Scientific Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

12.67%Per cent of shares held by top holders
HolderShares% Held
quant Money Managers Ltd.as of 30 Aug 202413.30m5.33%
UTI Asset Management Co. Ltd. (Investment Management)as of 30 Jun 20238.31m3.33%
White Oak Capital Partners Pte Ltd.as of 30 Jun 20234.08m1.63%
The Public Sector Pension Investment Boardas of 30 Jun 20232.66m1.07%
SSgA Funds Management, Inc.as of 05 Sep 20241.28m0.51%
Dimensional Fund Advisors LPas of 05 Sep 20241.12m0.45%
The Caisse de d�p�t et placement du Qu�becas of 31 Dec 2023554.31k0.22%
Motilal Oswal Asset Management Co. Ltd.as of 31 Aug 2024237.24k0.10%
Dimensional Fund Advisors Ltd.as of 30 Jun 202446.98k0.02%
DFA Australia Ltd.as of 31 Jul 202433.11k0.01%
More ▼
Data from 30 Jun 2023 - 31 Aug 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.